Recent approaches to overcoming multiple drug resistance in breast cancer using modified liposomes

References

• World Cancer Report. Boyle P, Levin B (Eds). WHO & International Agency for Research on Cancer, Lyon, France (2008).
   Google Scholar
• Hait WN, Yang JM. Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it. Semin. Oncol. 32(6 Suppl. 7), S16–S21 (2005).
   Google Scholar
• Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat. Rev. 34(4), 378–390 (2008).Excellent review of the concept of reversal of multidrug resistance.
   Google Scholar
• Miri R, Mehdipour A. Dihydropyridines and atypical MDR: a novel perspective of designing general reversal agents for both typical and atypical MDR. Bioorg. Med. Chem. 16(18), 8329–8334 (2008).
   Google Scholar
• Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist. Updat. 15(1–2), 50–61 (2012).
   Google Scholar
• Lo YL, Liu FI, Cherng JY. Effect of PSC 833 liposomes and intralipid on the transport of epirubicin in Caco-2 cells and rat intestines. J. Control. Release 76(1–2), 1–10 (2001).
   Google Scholar
• Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release 136(1), 21–29 (2009).
   Google Scholar
• Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist. Updat. 6(5), 271–279 (2003).Excellent review of the concept of liposomal-based strategies to overcome multidrug resistance.
   Google Scholar
• Thierry AR, Vige D, Coughlin SS, Belli JA, Dritschilo A, Rahman A. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J. 7(6), 572–579 (1993).
   Google Scholar
• Fan D, Bucana CD, O’Brian CA, Zwelling LA, Seid C, Fidler IJ. Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine–phosphatidylserine liposomes. Cancer Res. 50(12), 3619–3626 (1990).
   Google Scholar
• Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51(4), 691–743 (1999).
   Google Scholar
• Eckford PD, Sharom FJ. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem. J. 389(Pt 2), 517–526 (2005).
   Google Scholar
• Lo YL. Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem. Pharmacol. 60(9), 1381–1390 (2000).
   Google Scholar
• Kang DI, Kang HK, Gwak HS, Han HK, Lim SJ. Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells.Drug Deliv. 16(5), 261–267 (2009).
   Google Scholar
• Song CK, Balakrishnan P, Shim CK, Chung SJ, Kim DD. Enhanced in vitro cellular uptake of P-gp substrate by poloxamermodified liposomes (PMLs) in MDR cancer cells. J. Microencapsul. 28(6), 575–581 (2011).
   Google Scholar
• Ji X, Gao Y, Chen L, Zhang Z, Deng Y, Li Y. Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance. Int. J. Pharm. 422(1–2), 390–397 (2012).
   Google Scholar
• Zhao YZ, Dai DD, Lu CT et al. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer. Cancer Lett. 330(1), 74–83 (2013).
   Google Scholar
• Elhazzat J, El-Sayed MH. Advances in targeted breast cancer therapy. Curr. Breast Cancer Rep. 2(3), 146–151 (2010).
   Google Scholar
• Ogawara KI, Un K, Tanaka KI, Higaki K, Kimura T. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOXresistant tumor-bearing mice: involvement of cytotoxic effect on vascular endothelial cells.J. Control. Release 133(1), 4–10 (2009).
   Google Scholar
• Rastogi A. Nanooncology: the breast cancer story. Univ. Toronto Med. J. 88(3), 190–194 (2011).
   Google Scholar
• Brown S, Khan DR. The treatment of breast cancer using liposome technology. J. Drug Deliv. 2012, 212–965 (2012).
   Google Scholar
• Reynolds JG, Geretti E, Hendriks BS et al. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol. Appl. Pharmacol. 262(1), 1–10 (2012).
   Google Scholar
• Wang T, D’Souza GG, Bedi D et al. Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein.Nanomedicine (Lond.) 5(4), 563–574 (2010).n Original research describing the increased cytotoxicity and endosome-escaping property of doxorubicin-loaded liposomes (DOXIL®; Janssen Products, LP, NJ, USA) modified with a chimeric phage fusion coat protein specific towards breast cancer cells.
   Google Scholar
• Wicki A, Rochlitz C, Orleth A et al. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.Clin. Cancer Res. 18(2), 454–464 (2012).
   Google Scholar
• Shroff K, Kokkoli E. PEGylated liposomal doxorubicin targeted to α5b1-expressing MDA-MB-231 breast cancer cells. Langmuir 28(10), 4729–4736 (2012).Excellent review of the concept of reversal of multidrug resistance.
   Google Scholar